"A Novel New Treatment for Prostate Cancer With a Conditionally Replicating Herpes Simplex-1 Virus, G207."

According to an abstract submitted by the authors to the Annual Meeting of the American Urological Association, held May 1-6, 1999, in Dallas, Texas, "Introduction: We are exploring a novel form of cancer therapy using a modified herpes simplex virus (HSV) vector. G207 is a mutated HSV-1, with deletions of both ICP34.5 genes and insertion of the LacZ gene into the ICP6 gene. This attenuated HSV vector allows for both a direct cytolytic effect of viral infection, as well as the ability to generate additional viral particles to infect additional malignant cells. We propose that therapy using G207 will be efficacious in the treatment of prostate in situ. Methods: ...

Want to see the full article?

• Purchase this article for only $3.00